Qingyuan Y. Zhang
Harbin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
Journal: Journal for immunotherapy of cancer
Published: March 30, 2026
SOX5 Orchestrates Malignant Evolution via Promoter-Centric Chromatin Remodeling in MYC-Driven B-Cell Lymphoma.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 29, 2026
Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study.
Journal: American journal of hematology
Published: February 06, 2026
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: December 23, 2025
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 14, 2025
CCR7 orchestrates the malignant progression of memory B cells in MYC-overexpressing lymphoma.
Journal: Cell death and differentiation
Published: October 21, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Journal: Future oncology (London, England)
Published: October 18, 2025
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 16, 2025
Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 study.
Journal: Cancer pathogenesis and therapy
Published: July 04, 2025
Clinical Risk Stratification and Modifiable Risk Factors for Hepatitis B Virus-Related Follicular Lymphoma.
Journal: ImmunoTargets and therapy
Published: June 03, 2025
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
Journal: Signal transduction and targeted therapy
Published: May 19, 2025
Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: April 23, 2025
Last Updated: 09/26/2026